Request Trial
shutterstock_1595586766_ken_wolter
Ken Wolter / Shutterstock.com
6 March 2020PharmaClaire Irvine

Broad Institute down (but not out) in the European fight over CRISPR IP

Following the upholding in January 2020 of the revocation of the Broad Institute’s lead European patent (EP 2771468) by a European Patent Office (EPO) Appeal Board, there has been speculation that the University of California and its co-applicants (UC) have the upper hand in the European fight over the IP of clustered regularly interspaced short palindromic repeats (more commonly known as ‘CRISPR’), the latest incarnation of genome editing and deliberate alteration.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.
Pharma
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.
Pharma
USPTO director steps into Sun Pharma’s PTAB-ITC clash
31 July 2026   A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

More features

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
The UPC plugs another gap in its procedural rulebook
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
Fran Salisbury: ‘There’s nothing quite like finding the missing piece’
Patent litigator joins Baker Botts in London as UPC grows in significance
USPTO director steps into Sun Pharma’s PTAB-ITC clash
Where Big Pharma is betting big in the M&A boom
Buying the brains: Why is Big Pharma shopping for innovation?